BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2453829)

  • 1. Transfection of fibroblasts with activated c-myc confers resistance to antigrowth effects of interferon.
    Einat M; Kimchi A
    Oncogene; 1988 May; 2(5):485-91. PubMed ID: 2453829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle dependent growth factor regulation of gene expression.
    Morgan CJ; Pledger WJ
    J Cell Physiol; 1989 Dec; 141(3):535-42. PubMed ID: 2512304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cell cycle duration by c-myc levels.
    Karn J; Watson JV; Lowe AD; Green SM; Vedeckis W
    Oncogene; 1989 Jun; 4(6):773-87. PubMed ID: 2660073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive relaxation of Go-arrest controls and altered responsiveness to insulin, EGF and thrombin in CCL39 lung fibroblasts over-expressing myc and ras oncogenes.
    Pichon F; Seuwen K; Pouysségur J; Lagarde AE
    Oncogene; 1988 Oct; 3(4):373-81. PubMed ID: 3078948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse fibroblasts transformed with the human c-myc gene express a high level of mRNA but a low level of c-myc protein and are non-tumorigenic in nude mice.
    Ray R; Thomas S; Miller DM
    Oncogene; 1989 May; 4(5):593-600. PubMed ID: 2657574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative regulation of c-myc transcription involves myc family proteins.
    Cleveland JL; Huleihel M; Bressler P; Siebenlist U; Akiyama L; Eisenman RN; Rapp UR
    Oncogene Res; 1988; 3(4):357-75. PubMed ID: 2976141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of an exogenous c-myc gene is insufficient for transformation and tumorigenic conversion of established fibroblasts.
    Zerlin M; Julius MA; Cerni C; Marcu KB
    Oncogene; 1987 Mar; 1(1):19-27. PubMed ID: 3325875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells.
    Lepique AP; Moraes MS; Rocha KM; Eichler CB; Hajj GN; Schwindt TT; Armelin HA
    J Mol Endocrinol; 2004 Dec; 33(3):623-38. PubMed ID: 15591023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
    Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Na + flux inhibitors on induction of c-fos, c-myc, and ODC genes during cell cycle.
    Panet R; Amir I; Snyder D; Zonenshein L; Atlan H; Laskov R; Panet A
    J Cell Physiol; 1989 Jul; 140(1):161-8. PubMed ID: 2472417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts.
    Panet R; Marcus M; Atlan H
    J Cell Physiol; 2000 Jan; 182(1):109-18. PubMed ID: 10567922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
    Wang Y; Szekely L; Okan I; Klein G; Wiman KG
    Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
    Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
    Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cell cycle entry and G1 progression by CSF-1.
    Roussel MF
    Mol Reprod Dev; 1997 Jan; 46(1):11-8. PubMed ID: 8981358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta increases c-Myc proteolysis in mouse monocyte/macrophage leukemia cells.
    Hu X; Bies J; Wolff L
    Leuk Res; 2005 Nov; 29(11):1307-14. PubMed ID: 15939469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous c-myc gene overexpression interferes with early events in F9 cell differentiation.
    Onclercq R; Babinet C; Cremisi C
    Oncogene Res; 1989; 4(4):293-302. PubMed ID: 2671866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential dependence of the tumorigenicity of chemically transformed rat liver epithelial cells on autocrine production of transforming growth factor alpha.
    Duddy SK; Earp HS; Russell WE; Smith GJ; Grisham JW
    Cell Growth Differ; 1995 Mar; 6(3):251-61. PubMed ID: 7794793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of c-myc and the transferrin receptor in G1 synchronized M1 myeloid leukemia cells.
    Neckers LM; Tsuda H; Weiss E; Pluznik DH
    J Cell Physiol; 1988 May; 135(2):339-44. PubMed ID: 3372600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription of the c-myc oncogene is altered in spontaneously immortalized rodent fibroblasts.
    Tavassoli M; Shall S
    Oncogene; 1988 Apr; 2(4):337-45. PubMed ID: 3283652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative modes of c-myc regulation in growth factor-stimulated and differentiating cells.
    Nepveu A; Levine RA; Campisi J; Greenberg ME; Ziff EB; Marcu KB
    Oncogene; 1987; 1(3):243-50. PubMed ID: 2455262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.